Biotech and drug stocks
7.47k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop speciality drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three-month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called ‘Battling Cancer’.
Background
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the global financial markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.
How are these weighted?The stocks in this watchlist are weighted equally.
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| Biotech and drug stocks | +1.27% | - | - | - |
| ^GSPC | -0.30% | +4.01% | +23.66% | +5512.55% |
31 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 819.94 | +4.88 | +0.60% | 10:28 am GMT-4 | 517.20k | 2.71M | 779.28B |
| NVO | Novo Nordisk A/S | 135.62 | +2.82 | +2.12% | 10:28 am GMT-4 | 601.72k | 4.39M | 604.11B |
| JNJ | Johnson & Johnson | 146.622 | +1.34 | +0.92% | 10:29 am GMT-4 | 748.55k | 7.56M | 352.87B |
| MRK | Merck & Co., Inc. | 125.85 | +1.32 | +1.06% | 10:29 am GMT-4 | 977.69k | 8.37M | 318.75B |
| ABBV | AbbVie Inc. | 157.625 | +1.32 | +0.84% | 10:28 am GMT-4 | 800.14k | 5.60M | 278.35B |
| AZN | AstraZeneca PLC | 77.825 | +1.06 | +1.37% | 10:29 am GMT-4 | 705.39k | 5.21M | 241.29B |
| NVS | Novartis AG | 102.565 | +1.87 | +1.85% | 10:29 am GMT-4 | 231.47k | 1.48M | 209.27B |
| RHHBY | Roche Holding AG | 31.89 | +0.32 | +1.01% | 10:13 am GMT-4 | 67.43k | 2.96M | 203.94B |
| AMGN | Amgen Inc. | 304.155 | +3.15 | +1.05% | 10:29 am GMT-4 | 190.37k | 2.66M | 163.16B |
| PFE | Pfizer Inc. | 28.645 | +0.44 | +1.58% | 10:29 am GMT-4 | 7.18M | 41.61M | 162.32B |
| SNY | Sanofi | 48.655 | +0.82 | +1.72% | 10:28 am GMT-4 | 162.52k | 1.99M | 121.61B |
| VRTX | Vertex Pharmaceuticals Incorporated | 449.805 | +6.76 | +1.52% | 10:28 am GMT-4 | 132.02k | 1.04M | 116.07B |
| REGN | Regeneron Pharmaceuticals, Inc. | 978.32 | +8.41 | +0.87% | 10:27 am GMT-4 | 55.55k | 433.26k | 107.80B |
| GSK | GSK plc | 44.995 | +0.97 | +2.21% | 10:29 am GMT-4 | 663.64k | 3.10M | 94.40B |
| BMY | Bristol-Myers Squibb Company | 40.7627 | +0.51 | +1.27% | 10:29 am GMT-4 | 2.22M | 15.89M | 82.63B |
| GILD | Gilead Sciences, Inc. | 63.92 | -0.16 | -0.25% | 10:28 am GMT-4 | 1.36M | 6.90M | 79.63B |
| ZTS | Zoetis Inc. | 169.82 | +0.38 | +0.22% | 10:29 am GMT-4 | 368.32k | 3.64M | 77.49B |
| DSNKY | Daiichi Sankyo Company, Limited | 35.54 | +1.06 | +3.07% | 10:08 am GMT-4 | 1.54k | 203.31k | 68.15B |
| MRNA | Moderna, Inc. | 153.17 | +1.68 | +1.11% | 10:28 am GMT-4 | 793.25k | 4.01M | 58.70B |
| TAK | Takeda Pharmaceutical Company Limited | 13.285 | +0.26 | +1.96% | 10:29 am GMT-4 | 186.23k | 1.56M | 41.69B |
| HLN | Haleon plc | 8.385 | +0.01 | +0.06% | 10:28 am GMT-4 | 371.87k | 6.93M | 38.29B |
| BIIB | Biogen Inc. | 224.355 | +4.28 | +1.95% | 10:28 am GMT-4 | 133.66k | 1.21M | 32.67B |
| BAYRY | Bayer Aktiengesellschaft | 7.64 | -0.01 | -0.13% | 10:13 am GMT-4 | 336.11k | 2.09M | 30.02B |
| BNTX | BioNTech SE | 102.27 | +3.52 | +3.56% | 10:28 am GMT-4 | 362.32k | 709.15k | 24.65B |
| ARGX | argenx SE | 367.885 | +5.73 | +1.58% | 10:28 am GMT-4 | 37.13k | 273.19k | 23.00B |
| TEVA | Teva Pharmaceutical Industries Limited | 16.87 | -0.03 | -0.18% | 10:29 am GMT-4 | 1.19M | 9.81M | 19.11B |
| ALNY | Alnylam Pharmaceuticals, Inc. | 150.35 | +0.32 | +0.21% | 10:29 am GMT-4 | 86.70k | 548.16k | 19.02B |
| GMAB | Genmab A/S | 28.42 | +0.43 | +1.54% | 10:28 am GMT-4 | 74.26k | 483.40k | 18.33B |
| ALPMY | Astellas Pharma Inc. | 9.82 | +0.13 | +1.34% | 9:56 am GMT-4 | 1.98k | 340.51k | 17.61B |
| RPRX | Royalty Pharma plc | 26.92 | +0.53 | +2.01% | 10:28 am GMT-4 | 293.93k | 2.61M | 16.08B |
- Yahoo Finance Video
Ro CEO on GLP-1 drug shortage: US healthcare is '1 of 1'
GLP-1 medication supply constraints have left many patients grappling with the challenge of accessing these highly sought-after drugs. Ro CEO Zach Reitano joins Asking for a Trend to shed light on how his company aims to make supply information more readily available to patients in need. Reitano underscores Ro's core mission of "building goal-oriented healthcare" tailored to the individual needs of its patients. Recently, the company has been dedicating its efforts to addressing obesity, but they have also recognized "a massive shortage" in the availability of GLP-1 drugs. Consequently, Ro has been proactively "building products and services to help patients navigate and manage through these supply challenges." Reitano characterizes the current US healthcare landscape as "one of one," noting that "never before in healthcare has the majority of the US population been eligible for a drug." This situation has led to patients and providers "desperately" wanting access to these therapies, resulting in severe supply-demand dynamics, a challenge Reitano believes could persist for years to come. Reitano explains Ro's goal is to "crowdsource" supply information with its tracker, streamlining the process of accessing these drugs for both patients and healthcare providers. For more expert insight and the latest market action, click here to watch this full episode of Asking for a Trend. This post was written by Angel Smith
BenzingaHow To Earn $500 A Month From Pfizer Stock
Shares of Pfizer Inc. (NYSE:PFE) closed higher during Thursday's session, with the company's stock adding around 10% over the past month. Pfizer recently launched a multi-year cost reduction initiative aimed at saving approximately $1.5 billion by the end of 2027. This new program builds upon a $4 billion cost reduction plan announced last year. On May 1, Pfizer reported better-than-expected first-quarter financial results, posting adjusted EPS of 82 cents. That’s down 33% year over year, beatin
Insider MonkeyIs Eli Lilly And Co (NYSE:LLY) the Best Weight Loss Stock to Buy in 2024?
We recently published a list of Jim Cramer’s Top 10 Stock Picks for June. Since Eli Lilly And Co (NYSE:LLY) ranks higher in the list, the stock deserves a deeper look. But first, let’s see what Cramer was talking about during his programs earlier this week. Jim Cramer in a latest program lamented over Salesforce’s […]
